1. Home
  2. CRSP vs BDC Comparison

CRSP vs BDC Comparison

Compare CRSP & BDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$50.21

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Belden Inc

BDC

Belden Inc

HOLD

Current Price

$105.89

Market Cap

4.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
BDC
Founded
2013
1902
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.5B
IPO Year
2016
1994

Fundamental Metrics

Financial Performance
Metric
CRSP
BDC
Price
$50.21
$105.89
Analyst Decision
Buy
Strong Buy
Analyst Count
17
2
Target Price
$70.29
$162.50
AVG Volume (30 Days)
1.7M
510.9K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
0.16%
EPS Growth
N/A
23.13
EPS
N/A
1.30
Revenue
$289,590,000.00
$2,715,194,000.00
Revenue This Year
$807.72
$8.91
Revenue Next Year
$172.52
$4.70
P/E Ratio
N/A
$80.48
Revenue Growth
9169.85
10.33
52 Week Low
$35.38
$101.00
52 Week High
$78.48
$159.99

Technical Indicators

Market Signals
Indicator
CRSP
BDC
Relative Strength Index (RSI) 46.50 35.69
Support Level $44.82 N/A
Resistance Level $60.45 $121.62
Average True Range (ATR) 2.49 3.28
MACD -0.37 -0.53
Stochastic Oscillator 35.44 31.81

Price Performance

Historical Comparison
CRSP
BDC

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About BDC Belden Inc

Belden Inc is a supplier of complete connection solutions. It has two segments, Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions provides network infrastructure and broadband solutions, serving markets such as data centers, government, healthcare, and broadband and wireless service providers, with products including copper and fiber cable and connectivity solutions. Automation Solutions provides digitization and automation solutions that enable IT OT convergence and support acquisition, transmission, orchestration, and management, serving markets including Warehousing and Logistics, Energy, Transportation, and Discrete Manufacturing. The company operates in the Americas, EMEA, and APAC, with maximum revenue coming from the Americas.

Share on Social Networks: